Trastuzumab / HER2/EBBR2 Cancer Research Results

Tras, Trastuzumab: Click to Expand ⟱
Features:
Trastuzumab is a targeted therapy used in the treatment of certain types of cancer, most notably HER2-positive breast cancer.

It specifically targets the human epidermal growth factor receptor 2 (HER2), a protein that is overexpressed in some types of breast cancer and other cancers.
-Is a Her2 inhibitor used in breast cancer.

Trastuzumab has revolutionized the treatment of HER2-positive breast cancer, significantly improving both response rates and overall survival.
HER2/EBBR2, Human epidermal growth factor receptor 2: Click to Expand ⟱
Source:
Type:
Also called erbB-2 (or ERb-2) -Receptor tyrosine-protein kinase
HER2 is a protein that helps breast cancer cells grow quickly.
HER2/neu protein is a receptor tyrosine kinase that is normally involved in cell growth and division. However, in some cancers, the HER2/neu gene is overexpressed or mutated, leading to an overproduction of the protein. This can cause cells to grow and divide uncontrollably, leading to tumor formation.
Scientific Papers found: Click to Expand⟱
1101- CA,  Tras,    Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells
- in-vitro, BC, NA
ChemoSen↑, HER2/EBBR2↓, PI3K↓, Akt↓, mTOR↓, p62↑,
6136- CHr,  Tras,    Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cells
- in-vitro, BC, SkBr3 - in-vitro, BC, BT474 - in-vitro, Nor, MCF10
eff↑, HER2/EBBR2↓, p‑STAT3↓, PD-L1↓, ChemoSen↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Akt↓, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 2,  

Autophagy & Lysosomes ⓘ

p62↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 1,   PI3K↓, 1,   p‑STAT3↓, 1,  

Immune & Inflammatory Signaling ⓘ

PD-L1↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   eff↑, 1,  

Clinical Biomarkers ⓘ

HER2/EBBR2↓, 2,   PD-L1↓, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: HER2/EBBR2, Human epidermal growth factor receptor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:260  Target#:359  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page